Epitalon is a simple peptide comprised of four common amino acids in this sequence: Ala-Glu-Asp-Gly
It was first synthesized by Dr. Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Epitalon is a synthetic form of the primary fraction of Epithalamin – which is a protein concentrated in the pineal glands in a variety of mammals. It is being actively researched for its potential to improve a variety of age-associated problems in the following ways:
improving retinal health (ie. preventing vision loss) 
improving the regulation of insulin, melatonin, and cortisol levels –
In preclinical and clinical studies, Epitalon has been administered subcutaneously, since peptides comprised of common amino acids are highly susceptible to rapid degradation in the stomach. However, small peptides (with low hydrophobicity) such as Epitalon can be absorbed under the tongue (sublingual).
In clinical trials, Epitalon is being evaluated at 1-10 mg/day, using either sublingual or subcutaneous administration.
Selected preclinical research findings
Epitalon has been shown to reduce spontaneous tumor development in mice :
Epitalon has been shown to increase lifespan and prevent leukemia :
The potential preventive effect of the synthetic pineal peptide Epitalon on spontaneous tumorigenesis in mice was studied. One-year-old female C3H/He mice were kept for 6.5 months under standard conditions and Epitalon was injected 5 times a week. Long-term exposure to Epitalon in small doses did not show any toxic effect. Treatment with Epitalon decreased the number of tumor-bearing mice with malignant tumors and prevented the development of metastases. Spontaneous tumors of the reproductive organs (mammary glands and ovaries) were predominant in both groups of mice (control and experimental).
The mammary gland tumors were different variants of invasive ductal carcinomas. In the ovaries, granulosa-cell tumors were found. Tumors were in the minority in other organs and had benign characteristics. In control mice, metastases were found in 3 out of 9 tumor bearing mice, all of them being from tumors of the reproductive organs. Treatment with Epitalon slowed down the development of metastases from spontaneous tumors, and no metastases were found in the experimental mice. These data highlight the antimetastatic effect of Epitalon.
Adapted from:G. Kossoy, V. N. Anisimov, H. Ben-Hur, N. Kossoy, and I. Zusman, “Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice.,” In Vivo, vol. 20, no. 2, pp. 253–7.
From the age of 3 months until their natural deaths, female outbred Swiss-derived SHR mice were subcutaneously injected on 5 consecutive days every month with 0.1 ml of normal saline (control) or with 1.0 µg/mouse (∼30–40 µg/kg) of Epitalon dissolved in 0.1 ml saline. There were 54 mice in each group. The results of this study show that treatment with Epitalon did not influence food consumption, body weight or mean life span of mice. However, itdecreased the frequency of chromosome aberrations in bone marrow cells (by 17.1%, P < 0.05). It also increased by 13.3% the life span of the last 10% of the survivors (P < 0.01) and by 12.3% the maximum life span in comparison with the control group. We also found that treatment with Epitalon inhibited the development of leukemia (6.0-fold), as compared with the control group. The data obtained suggest a geroprotector activity of Epitalon and the safety of its long-term administration in mice.
Adapted from: V. N. Anisimov et al., “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice,” Biogerontology, vol. 4, no. 4, pp. 193–202, 2003.
Selected clinical research findings
Epithalamin has been shown to inhibit rapid aging of elderly people in a groundbreaking 15 year study :
Over three years, 39 coronary patients received, in addition to basic therapy, regular courses of epithalamin, while 40 coronary patients (control group) received basic therapy alone. Long-term treatment with epithalamin decelerated aging of the cardiovascular system, prevented age-associated impairment of physical endurance, normalized circadian rhythm of melatonin production and carbohydrate and lipid metabolism. A significantly lower mortality in the group of patients treated with epithalamin indicates a geroprotective [anti-aging] effect of the peptide preparation from the pineal gland.
AA = Actual age CVS FA = Cardiovascular system functional age
Cardiovascular system FA was evaluated using a mathematical formula based on the threshold exercise power and hemodynamics at the peak of threshold exercise.
Adapted from: O. V. Korkushko, V. K. Khavinson, V. B. Shatilo, and I. A. Antonyk-Sheglova, “Peptide Geroprotector from the Pituitary Gland Inhibits Rapid Aging of Elderly People: Results of 15-Year Follow-Up,” Bull. Exp. Biol. Med., vol. 151, no. 3, pp. 366–369, Jul. 2011
Conclusion: This 15-year follow-up of two groups of elderly patients with rapidly aging cardiovascular systems showed that long-term treatment prevented age-associated reduction of physical endurance, normalized lipid metabolism, and significantly reduced overall mortality.
*The information herein is for educational and informational purposes only. THIS PRODUCT IS FOR RESEARCH USE ONLY. For use in animal studies, all research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).
Storage: Lyophilized peptide should be stored at -20°C (freezer), and the reconstituted peptide solution at 4°C (refrigerated). Use within 24 months. Once reconstituted use within 30 days. Do not freeze once reconstituted.
 C. Bartsch, The pineal gland and cancer : neuroimmunoendocrine mechanisms in malignancy. Springer, 2001.
 V. K. Khavinson, A. T. Kopylov, B. V. Vaskovsky, G. A. Ryzhak, and N. S. Lin’kova, “Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland,” Bull. Exp. Biol. Med., vol. 164, no. 1, pp. 41–43, Nov. 2017.
 V. K. Khavinson, “Peptides and Ageing.,” Neuro Endocrinol. Lett., vol. 23 Suppl 3, pp. 11–144, 2002.
 I. A. Vinogradova, A. V. Bukalev, M. A. Zabezhinski, A. V. Semenchenko, V. K. Khavinson, and V. N. Anisimov, “Geroprotective effect of Ala-Glu-Asp-Gly peptide in male rats exposed to different illumination regimens,” Bull. Exp. Biol. Med., vol. 145, no. 4, pp. 472–477, Apr. 2008.
 I. A. Vinogradova, A. V. Bukalev, M. A. Zabezhinski, A. V. Semenchenko, V. K. Khavinson, and V. N. Anisimov, “Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes,” Bull. Exp. Biol. Med., vol. 144, no. 6, pp. 825–830, Dec. 2007.
 V. N. Anisimov et al., “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice,” Biogerontology, vol. 4, no. 4, pp. 193–202, 2003.
 L. S. Kozina, A. V. Arutjunyan, and V. K. Khavinson, “Antioxidant properties of geroprotective peptides of the pineal gland,” Arch. Gerontol. Geriatr., vol. 44, pp. 213–216, Jan. 2007.
 G. Kossoy et al., “Epitalon and colon carcinogenesis in rats: Proliferative activity and apoptosis in colon tumors and mucosa,” Int. J. Mol. Med., vol. 12, no. 4, pp. 473–477, Oct. 2003.
 V. N. Anisimov et al., “Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice,” Int. J. Cancer, vol. 101, no. 1, pp. 7–10, Sep. 2002.
 G. Kossoy, V. N. Anisimov, H. Ben-Hur, N. Kossoy, and I. Zusman, “Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice.,” In Vivo, vol. 20, no. 2, pp. 253–7.
 V. Khavinson, M. Razumovsky, S. Trofimova, R. Grigorian, and A. Razumovskaya, “Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa.,” Neuro Endocrinol. Lett., vol. 23, no. 4, pp. 365–8, Aug. 2002.
 V. Khavinson, N. Goncharova, and B. Lapin, “Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys.,” Neuro Endocrinol. Lett., vol. 22, no. 4, pp. 251–4, Aug. 2001.
 R. G. Goya, G. M. Cónsole, C. B. Hereñú, O. A. Brown, and O. J. Rimoldi, “Thymus and Aging: Potential of Gene Therapy for Restoration of Endocrine Thymic Function in Thymus-Deficient Animal Models,” Gerontology, vol. 48, no. 5, pp. 325–328, 2002.
 N. D. Goncharova, A. A. Vengerin, V. K. Khavinson, and B. A. Lapin, “Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas,” Exp. Gerontol., vol. 40, no. 1–2, pp. 51–57, Jan. 2005.
 O. V. Korkushko, V. K. Khavinson, V. B. Shatilo, and I. A. Antonyk-Sheglova, “Peptide Geroprotector from the Pituitary Gland Inhibits Rapid Aging of Elderly People: Results of 15-Year Follow-Up,” Bull. Exp. Biol. Med., vol. 151, no. 3, pp. 366–369, Jul. 2011.